Brg1 is required to maintain colorectal cancer stem cells.
Brg1
chromatin remodeling regulator
colorectal cancer
tumor stem cell
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
08
06
2021
received:
20
12
2020
accepted:
13
07
2021
pubmed:
21
8
2021
medline:
1
1
2022
entrez:
20
8
2021
Statut:
ppublish
Résumé
Tumor cells capable of self-renewal and continuous production of progeny cells are called tumor stem cells (TSCs) and are considered to be potential therapeutic targets. However, the mechanisms underlying the survival and function of TSCs are not fully understood. We previously reported that chromatin remodeling regulator Brg1 is essential for intestinal stem cells in mice and Dclk1 is an intestinal TSC marker. In this study, we investigated the role of Brg1 in Dclk1
Substances chimiques
Nuclear Proteins
0
Transcription Factors
0
SMARCA4 protein, human
EC 3.6.1.-
Smarca4 protein, mouse
EC 3.6.1.-
DNA Helicases
EC 3.6.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-269Informations de copyright
© 2021 The Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Références
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68: 394-424.
Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol 2011; 6: 479-507.
Jung G, Hernández-Illán E, Moreira L, et al. Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nat Rev Gastroenterol Hepatol 2020; 17: 111-130.
Vaiopoulos AG, Athanasoula KC, Papavassiliou AG. Epigenetic modifications in colorectal cancer: molecular insights and therapeutic challenges. Biochim Biophys Acta 2014; 1842: 971-980.
Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011; 11: 481-492.
Euskirchen G, Auerbach RK, Snyder M. SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse functions. J Biol Chem 2012; 287: 30897-30905.
Shen J, Peng Y, Wei L, et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov 2015; 5: 752-767.
Alpsoy A, Dykhuizen EC. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. J Biol Chem 2018; 293: 3892-3903.
Marquez-Vilendrer SB, Thompson K, Lu L, et al. Mechanism of BRG1 silencing in primary cancers. Oncotarget 2016; 7: 56153-56169.
von Figura G, Fukuda A, Roy N, et al. The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma. Nat Cell Biol 2014; 16: 255-267.
Guerrero-Martínez JA, Reyes JC. High expression of SMARCA4 or SMARCA2 is frequently associated with an opposite prognosis in cancer. Sci Rep 2018; 8: 2043.
Sun A, Tawfik O, Gayed B, et al. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers. Prostate 2007; 67: 203-213.
Tsuda M, Fukuda A, Roy N, et al. The BRG1/SOX9 axis is critical for acinar cell-derived pancreatic tumorigenesis. J Clin Invest 2018; 128: 3475-3489.
Lin S, Jiang T, Ye L, et al. The chromatin-remodeling enzyme BRG1 promotes colon cancer progression via positive regulation of WNT3A. Oncotarget 2016; 7: 86051-86063.
Watanabe T, Semba S, Yokozaki H. Regulation of PTEN expression by the SWI/SNF chromatin-remodelling protein BRG1 in human colorectal carcinoma cells. Br J Cancer 2011; 104: 146-154.
Pyo JS, Son BK, Oh D, et al. BRG1 is correlated with poor prognosis in colorectal cancer. Hum Pathol 2018; 73: 66-73.
Holik AZ, Young M, Krzystyniak J, et al. Brg1 loss attenuates aberrant Wnt-signalling and prevents Wnt-dependent tumourigenesis in the murine small intestine. PLoS Genet 2014; 10: e1004453.
Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
Takada Y, Fukuda A, Chiba T, et al. Brg1 plays an essential role in development and homeostasis of the duodenum through regulation of Notch signaling. Development 2016; 143: 3532-3539.
Holik AZ, Krzystyniak J, Young M, et al. Brg1 is required for stem cell maintenance in the murine intestinal epithelium in a tissue-specific manner. Stem Cells 2013; 31: 2457-2466.
Gerbe F, Legraverend C, Jay P. The intestinal epithelium tuft cells: specification and function. Cell Mol Life Sci 2012; 69: 2907-2917.
Vega KJ, May R, Sureban SM, et al. Identification of the putative intestinal stem cell marker doublecortin and CaM kinase-like-1 in Barrett's esophagus and esophageal adenocarcinoma. J Gastroenterol Hepatol 2012; 27: 773-780.
Bailey JM, Alsina J, Rasheed ZA, et al. DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014; 146: 245-256.
Li L, Bellows CF. Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line. Chin J Cancer Res 2013; 25: 134-142.
Maruno T, Fukuda A, Goto N, et al. Visualization of stem cell activity in pancreatic cancer expansion by direct lineage tracing with live imaging. Elife 2021; 10: e55117.
Nakanishi Y, Seno H, Fukuoka A, et al. Dclk1 distinguishes between tumor and normal stem cells in the intestine. Nat Genet 2013; 45: 98-103.
Sumi-Ichinose C, Ichinose H, Metzger D, et al. SNF2beta-BRG1 is essential for the viability of F9 murine embryonal carcinoma cells. Mol Cell Biol 1997; 17: 5976-5986.
Solar M, Cardalda C, Houbracken I, et al. Pancreatic exocrine duct cells give rise to insulin-producing beta cells during embryogenesis but not after birth. Dev Cell 2009; 17: 849-860.
Yamaga Y, Fukuda A, Nakanishi Y, et al. Gene expression profile of Dclk1+ cells in intestinal tumors. Dig Liver Dis 2018; 50: 1353-1361.
de Sousa e Melo F, Kurtova AV, Harnoss JM, et al. A distinct role for Lgr5+ stem cells in primary and metastatic colon cancer. Nature 2017; 543: 676-680.
Shimokawa M, Ohta Y, Nishikori S, et al. Visualization and targeting of LGR5+ human colon cancer stem cells. Nature 2017; 545: 187-192.
Goto N, Fukuda A, Yamaga Y, et al. Lineage tracing and targeting of IL17RB+ tuft cell-like human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2019; 116: 12996-13005.
Goto N, Ueo T, Fukuda A, et al. Distinct roles of HES1 in normal stem cells and tumor stem-like cells of the intestine. Cancer Res 2017; 77: 3442-3454.
Hiramatsu Y, Fukuda A, Ogawa S, et al. Arid1a is essential for intestinal stem cells through Sox9 regulation. Proc Natl Acad Sci U S A 2019; 116: 1704-1713.
Griffin CT, Brennan J, Magnuson T. The chromatin-remodeling enzyme BRG1 plays an essential role in primitive erythropoiesis and vascular development. Development 2008; 135: 493-500.
Naidu SR, Love IM, Imbalzano AN, et al. The SWI/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells. Oncogene 2009; 28: 2492-2501.
Barker N, Hurlstone A, Musisi H, et al. The chromatin remodelling factor Brg-1 interacts with beta-catenin to promote target gene activation. EMBO J 2001; 20: 4935-4943.
Shi J, Whyte WA, Zepeda-Mendoza CJ, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev 2013; 27: 2648-2662.
Vermeulen L, de Sousa e Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 2010; 12: 468-476.
Zhang HL, Wang P, Lu MZ, et al. c-Myc maintains the self-renewal and chemoresistance properties of colon cancer stem cells. Oncol Lett 2019; 17: 4487-4493.